[go: up one dir, main page]

ES2012116A6 - Metodo para la produccion de una composicion oftalmica a base de ciclosporina de uso por via local. - Google Patents

Metodo para la produccion de una composicion oftalmica a base de ciclosporina de uso por via local.

Info

Publication number
ES2012116A6
ES2012116A6 ES8802718A ES8802718A ES2012116A6 ES 2012116 A6 ES2012116 A6 ES 2012116A6 ES 8802718 A ES8802718 A ES 8802718A ES 8802718 A ES8802718 A ES 8802718A ES 2012116 A6 ES2012116 A6 ES 2012116A6
Authority
ES
Spain
Prior art keywords
cyclosporin
lacrimal
composition
topical administration
corn oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8802718A
Other languages
English (en)
Inventor
Renee Kaswan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Georgia Research Foundation Inc UGARF
Original Assignee
University of Georgia Research Foundation Inc UGARF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/092,466 external-priority patent/US4839342A/en
Application filed by University of Georgia Research Foundation Inc UGARF filed Critical University of Georgia Research Foundation Inc UGARF
Publication of ES2012116A6 publication Critical patent/ES2012116A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)

Abstract

METODO PARA LA PRODUCCION DE UNA COMPOSICION OFTALMICA A BASE DE CICLOSPORINA DE USO POR VIA LOCAL, PARA MEJORAR O RESTABLECER LA FUNCION DE LAS GLANDULAS LACRIMALES, CARACTERIZADO PORQUE COMPRENDE AÑADIR ENTRE 0,01% Y EL NIVEL DE SATURACION DE CICLOSPORINA A UN EXCIPIENTE FARMACEUTICAMENTE ACEPTABLE ELEGIDO ENTRE ACEITE DE MAIZ, ACEITE DE OLIVA, ACEITE MINERAL, VASELINA, DIMETILSULFOXIDO, ALCOHOL POLIVINILICO, LIPOSOMA, FLUIDO SILICONICO O UNA MEZCLA DE LOS ANTERIORES.
ES8802718A 1987-09-03 1988-09-02 Metodo para la produccion de una composicion oftalmica a base de ciclosporina de uso por via local. Expired - Lifetime ES2012116A6 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/092,466 US4839342A (en) 1987-09-03 1987-09-03 Method of increasing tear production by topical administration of cyclosporin
US11721887A 1987-11-04 1987-11-04
US18782388A 1988-04-29 1988-04-29

Publications (1)

Publication Number Publication Date
ES2012116A6 true ES2012116A6 (es) 1990-03-01

Family

ID=27377210

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8802718A Expired - Lifetime ES2012116A6 (es) 1987-09-03 1988-09-02 Metodo para la produccion de una composicion oftalmica a base de ciclosporina de uso por via local.

Country Status (12)

Country Link
US (1) US5411952A (es)
EP (1) EP0391909B1 (es)
JP (1) JPH0667850B2 (es)
KR (1) KR920003601B1 (es)
AT (1) ATE109970T1 (es)
DE (1) DE3851152T2 (es)
DK (1) DK54390A (es)
ES (1) ES2012116A6 (es)
GR (1) GR1000558B (es)
IE (1) IE65582B1 (es)
PH (1) PH24814A (es)
WO (1) WO1989001772A1 (es)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
ZA927277B (en) * 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
DK0642332T3 (da) 1992-05-13 1997-06-16 Sandoz Ltd Ophthalmiske præparater indeholdende cyclosporin
US5830508A (en) 1992-08-06 1998-11-03 Deo Corporation Composition for treating dry eye
US5366739A (en) * 1992-08-06 1994-11-22 Deo Corporation Method of ophthalmic drug delivery
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5474979A (en) * 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
ES2169351T3 (es) 1996-02-13 2002-07-01 Searle & Co Combinaciones que tienen efectos inmunosupresores, que contienen inhibidores de ciclooxigenasa-2 y 5-lipoxigenasa.
EP0880363B1 (en) * 1996-02-13 2002-09-11 G.D. SEARLE & CO. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a 4 hydrolase inhibitor
CA2238029A1 (en) * 1996-03-05 1997-09-12 Medinox, Inc. Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
DE69840586D1 (de) 1997-10-08 2009-04-02 Isotechnika Inc Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
US6861411B1 (en) 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5981607A (en) * 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
GB9818278D0 (en) * 1998-08-22 1998-10-14 Smith & Nephew Compositions
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6255280B1 (en) 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
CN1268623C (zh) * 1999-10-15 2006-08-09 苏坎波公司 组合物和使该组合物稳定的方法
EP1142566B1 (fr) 2000-04-07 2003-10-01 Laboratoire Medidom S.A. Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
WO2002098376A1 (en) * 2001-06-06 2002-12-12 The Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
SI1436321T1 (sl) * 2001-10-19 2006-12-31 Isotechnika Inc Sinteza analogov ciklosporina
KR20030065831A (ko) * 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
US6930127B2 (en) * 2002-08-15 2005-08-16 Eaton Veterinary Laboratories, Inc. Veterinary treatment of ophthalmic disease in animals using topical tacrolimus
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7538084B2 (en) * 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
EP1608347B1 (en) * 2003-03-28 2014-08-13 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050059583A1 (en) * 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN100548271C (zh) 2004-01-20 2009-10-14 阿勒根公司 用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
US7923471B2 (en) * 2004-05-14 2011-04-12 Alcon, Inc. Method of treating dry eye disorders and uveitis
US20050277584A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
EP1811979B1 (en) * 2004-09-27 2008-11-05 Sigmoid Pharma Limited Microcapsules comprising a methylxanthine and a corticosteroid
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
EP1812037A4 (en) * 2004-10-06 2009-11-11 Amr Technology Inc ALKYNES OF CYCLOSPORINE AND THEIR USEFUL AS PHARMACEUTICAL AGENTS
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
WO2006073786A2 (en) * 2004-12-30 2006-07-13 Bausch & Lomb Incorporated Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
CA2615990A1 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
EP3103468B1 (en) * 2005-10-14 2020-07-15 Allergan, Inc. Prevention of drug-associated keratoconjunctivitis with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US20070225217A1 (en) 2005-11-09 2007-09-27 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
BRPI0707612B8 (pt) 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
US7655625B2 (en) * 2006-02-13 2010-02-02 Allergan, Inc. Methods of treating blepharospasm using cyclosporine components
US7557082B2 (en) 2006-03-03 2009-07-07 Allergan, Inc. Treatment with cyclosporin A
US20070219127A1 (en) * 2006-03-20 2007-09-20 Walt John G Cyclosporin a compositions
WO2007112052A2 (en) 2006-03-23 2007-10-04 Macusight, Inc. Formulations and methods for vascular permeability-related diseases or conditions
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US20080146497A1 (en) * 2006-07-25 2008-06-19 Graham Richard S Cyclosporin Compositions
EP2061440A2 (en) 2007-04-04 2009-05-27 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
CA2686234A1 (en) * 2007-05-04 2008-11-13 Allergan, Inc. Use of cyclosporines in the treatment of patients with intraocular lenses
US20090081277A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Pharmaceutical formulations and methods for treating ocular conditions
MX2010003364A (es) * 2007-10-08 2010-07-06 Lux Biosciences Inc Composiciones oftalmicas que comprenden inhibidores de calcineurina o inhibidores de mtor.
ITMI20080003A1 (it) * 2008-01-02 2009-07-03 Alfredo Pulpito Composizioni per uso oftalmico
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd MYCOPHENOLIC SODIUM ACID SOLUTIONS WITH PH SPECIFIC FOR THE TREATMENT OF OCULAR DISORDERS
US9445975B2 (en) * 2008-10-03 2016-09-20 Access Business Group International, Llc Composition and method for preparing stable unilamellar liposomal suspension
EA201190088A1 (ru) 2009-01-08 2012-02-28 Аллерган, Инк. Композиции циклоспорина для усиления роста ногтей
US20110009339A1 (en) * 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
JP5640079B2 (ja) 2009-05-18 2014-12-10 シグモイド・ファーマ・リミテッドＳｉｇｍｏｉｄ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ 油滴含有組成物
KR101778316B1 (ko) 2009-06-05 2017-09-13 알러간, 인코포레이티드 인공 눈물 및 치료학적 용도
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
CN102573802A (zh) 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
EP2515864A4 (en) * 2009-12-23 2013-09-11 Psivida Inc DELAYED RELEASE DELIVERY DEVICES
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
AU2012339695B2 (en) 2011-11-15 2017-10-05 Allergan, Inc. Sustained action formulation of cyclosporin Form 2
ES2666191T3 (es) 2011-11-15 2018-05-03 Allergan, Inc. Un proceso para la cristalización de la forma 2 de la ciclosporina A
JP6363506B2 (ja) 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US20130266615A1 (en) * 2012-04-10 2013-10-10 Bin Wu Non-immunogenic delivery vehicle for beta-, gamma-, and delta-tocopherols and methods of using and making same
WO2013158296A1 (en) * 2012-04-20 2013-10-24 Howard University Method of treating an ocular disease and compositions effective for treating an ocular disease
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
EP3215127B1 (en) 2014-11-07 2020-10-28 Sublimity Therapeutics Limited Compositions comprising cyclosporin
JP6768653B2 (ja) 2014-11-25 2020-10-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 安定したオメガ−３眼科用組成物
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3608073A (en) * 1968-07-16 1971-09-21 Barnes Hind Pharm Inc Emulsion of pilocarpine for ophthalmic use
US4210581A (en) * 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (es) * 1975-11-04 1979-12-28 Sandoz Ag
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US4115544A (en) * 1976-08-18 1978-09-19 Alza Corporation Ocular system made of bioerodible esters having linear ether
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
SE445174B (sv) * 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
US4215199A (en) * 1978-06-05 1980-07-29 Sandoz Ltd. Antibiotic production
SE448386B (sv) * 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
EP0098456B1 (en) * 1980-02-14 1989-05-24 Sandoz Ag Peptides comprising a (1s,2r,3r)- or (1r,2s,3s)-1-nitrilo-1-carbonyl-3-methyl-2-oxy-heptane or -hept-5-ene residue useful in the total synthesis of cyclosporins, and processes for their production
US4396542A (en) * 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
DE3260468D1 (en) * 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
WO1983001252A1 (en) * 1981-10-09 1983-04-14 Hakanson, Rolf A drug based on a substance p antagonist
EP0145714A1 (en) * 1983-05-25 1985-06-26 Alcon Laboratories, Inc. Ophthalmic gel
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
EP0170623B1 (en) * 1984-08-02 1990-11-28 Sandoz Ag Novel pharmaceutical use of (nva)2-cyclosporine
GB8422253D0 (en) * 1984-09-04 1984-10-10 Sandoz Ltd Organic compounds
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
US4649047A (en) * 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
JPS61249918A (ja) * 1985-04-26 1986-11-07 Yutaka Mizushima 点眼剤
US4745100A (en) * 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US4861580A (en) * 1985-10-15 1989-08-29 The Liposome Company, Inc. Composition using salt form of organic acid derivative of alpha-tocopheral
GB8528032D0 (en) * 1985-11-13 1985-12-18 Ici Plc Ocular treatment
US4923699A (en) * 1988-06-03 1990-05-08 Kaufman Herbert E Eye treatment suspension

Also Published As

Publication number Publication date
PH24814A (en) 1990-10-30
JPH0667850B2 (ja) 1994-08-31
EP0391909A1 (en) 1990-10-17
JPH03503159A (ja) 1991-07-18
KR920003601B1 (ko) 1992-05-04
US5411952A (en) 1995-05-02
WO1989001772A1 (en) 1989-03-09
EP0391909B1 (en) 1994-08-17
GR880100578A (en) 1989-06-22
GR1000558B (el) 1992-08-26
ATE109970T1 (de) 1994-09-15
IE882663L (en) 1989-03-03
KR890701084A (ko) 1989-12-19
DK54390A (da) 1990-05-03
DK54390D0 (da) 1990-03-01
DE3851152T2 (de) 1995-01-26
IE65582B1 (en) 1995-11-01
DE3851152D1 (de) 1994-09-22

Similar Documents

Publication Publication Date Title
ES2012116A6 (es) Metodo para la produccion de una composicion oftalmica a base de ciclosporina de uso por via local.
AU781975B2 (en) Pharmaceutical composition for ophthalmic use
AU784017B2 (en) Solutions containing epinastine
AU594427B2 (en) Anti-inflammatory compounds for opthalmic use
EP0917873B1 (en) Eyedrops
ZA200201903B (en) Use of H1 antagonist and a safe steriod to treat eye conditions.
GB2075341B (en) Pharmaceutical compositions
Murube et al. Classification of artificial tears: II: Additives and commercial formulas
US4197301A (en) Topical ophthalmic use of Prazosin
US5620970A (en) Topical ophthalmic carbonic anhydrase inhibitor formulations
KR900701259A (ko) 다가 소염제
US5679713A (en) Pharmaceutical composition containing carbachol and other cholinergic substances
KR950000138A (ko) 안(眼)국소용 조성물
US5908866A (en) Pharmaceutical composition containing carbachol and other cholinergic substances
KR900004800B1 (ko) 항녹내장 조성물 및 이의 제조방법
JP2558147B2 (ja) 免疫性疾患治療剤
US4312863A (en) Treatment of glaucoma
US5457126A (en) Use of lodoxamide to treat ophthalmic allergic conditions
CA2354765A1 (en) The process for manufacturing formulation of topical beta blockers with improved efficacy
CA2015427A1 (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
AU723823B2 (en) Use of chloride channel blockers for providing a neuroprotective effect to the mammalian eye
Woodward et al. Effect of cimetidine and pyrilamine on histamine-induced ocular surface hyperemia
WO1998056380A1 (en) Method to reverse mydriasis
EP0375319A2 (en) Angiotensin converting enzyme inhibitors in the treatment of glaucoma
IT1241928B (it) Composizione oftalmica per l'uso nel mantenimento della midriasi oculare

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2008-09-02

FD1A Patent lapsed

Effective date: 20080903